Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Juli 2017

Planlagt Fastgjort Låst Flyttet Genmab
985 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • Legolas23L Offline
    Legolas23L Offline
    Legolas23
    wrote on sidst redigeret af
    #758

    En endelig godkendelse for ALCYONE vil udløse 102 kr og være lig med de sidste 15% i analysen. Når man ved patientgrunflaget bliver fordoblet i 1. Linie er det også lavt og ikke realistisk sat.

    1 Reply Last reply
    0
    • F Offline
      F Offline
      flottenschmecker
      wrote on sidst redigeret af
      #759

      Det er lige det. Seler og livrem analyser i biotek er i bedste fald ubrugelige

      1 Reply Last reply
      0
      • nohopeN Offline
        nohopeN Offline
        nohope
        wrote on sidst redigeret af
        #760

        Hvad sker der med patientgrundlaget i 2. og efterfølgende linier når Dara bliver taget i brug i 1. linie ?

        1 Reply Last reply
        0
        • G Offline
          G Offline
          GeorgeBest
          wrote on sidst redigeret af
          #761

          Man vel forestille sig at for de patienter der ikke får dara I 1. linie, vil få det I anden linie, når første behandling ikke mere virker

          1 Reply Last reply
          0
          • nohopeN Offline
            nohopeN Offline
            nohope
            wrote on sidst redigeret af
            #762

            Man kunne også forestille sig at 2. linie ville blive mindsket.....

            1 Reply Last reply
            0
            • F Offline
              F Offline
              flottenschmecker
              wrote on sidst redigeret af
              #763

              SC dara maintenance, darkombo med andre medikamenter og så kan dara nok alligevel ikke forvente 100pct penetration i 1st line

              1 Reply Last reply
              0
              • F Offline
                F Offline
                flottenschmecker
                wrote on sidst redigeret af
                #764

                Så dara vil nok ændre landskabet markant

                1 Reply Last reply
                0
                • G Offline
                  G Offline
                  gentogen
                  wrote on sidst redigeret af
                  #765

                  Nyt studie: Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma (MASTER) (KRdD = Kyprolis (Carfilzomib), Revlimid (Lenalidomide), dexamethasone, Darzalex (Daratumumab)

                  1 Reply Last reply
                  0
                  • G Offline
                    G Offline
                    gentogen
                    wrote on sidst redigeret af
                    #766

                    Amgen og Janssen.https://clinicaltrials.gov/ct2/show/NCT03224507?term=daratumumab&rcv_s=07%2F01%2F2017&rcv_e=07%2F24%2F2017&rank=3

                    1 Reply Last reply
                    0
                    • B Offline
                      B Offline
                      bikube
                      wrote on sidst redigeret af
                      #767

                      HCT - er det stamceller ??

                      1 Reply Last reply
                      0
                      • nohopeN Offline
                        nohopeN Offline
                        nohope
                        wrote on sidst redigeret af
                        #768

                        Fåk - det hele er rødt.

                        1 Reply Last reply
                        0
                        • nohopeN Offline
                          nohopeN Offline
                          nohope
                          wrote on sidst redigeret af
                          #769

                          Jeg går op og lægger mig, Hans Christian.

                          1 Reply Last reply
                          0
                          • G Offline
                            G Offline
                            gentogen
                            wrote on sidst redigeret af
                            #770

                            Ja. This trial will assess the safety and efficacy of an induction therapy using the combination of dexamethasone, lenalidomide (revlimid), daratumumab (Darzalex) and carfilzomib (Kyprolis) to treat patients with newly diagnosed multiple myeloma. The therapy with KRdD (Kyprolis, Revlimid, dexamethasone, Darzalex) will be followed by autologous hematopoietic cell transplantation (auto-HCT) and KRdD consolidation.

                            1 Reply Last reply
                            0
                            • G Offline
                              G Offline
                              gentogen
                              wrote on sidst redigeret af
                              #771

                              Versus KRsD alene

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #772

                                Half-way
                                the year the number of Dara trials up by almost 50%...

                                1 Reply Last reply
                                0
                                • P Offline
                                  P Offline
                                  Plimsoller
                                  wrote on sidst redigeret af
                                  #773

                                  301 Moved Permanently

                                  favicon

                                  (penge.borsen.dk)

                                  1 Reply Last reply
                                  0
                                  • SolsenS Offline
                                    SolsenS Offline
                                    Solsen
                                    wrote on sidst redigeret af
                                    #774

                                    Indtil nu har vi ikke hørt, at der er nogen der er kureret af dara og taget af behandling - så maintenance i 5-10 for mange der behandles first line vil skæppe godt i kassen. Antallet af second- og senere linier vil mindskes i de kommende år, hvis first line kommer ud med mega succes.

                                    1 Reply Last reply
                                    0
                                    • B Offline
                                      B Offline
                                      bikube
                                      wrote on sidst redigeret af
                                      #775

                                      Tak for svar gentogen

                                      1 Reply Last reply
                                      0
                                      • B Offline
                                        B Offline
                                        BiotechPro
                                        wrote on sidst redigeret af
                                        #776

                                        US integrated Darzalex sales figures for June have been released by Symphony Health Solutions. Darzalex sales were USD 81.5m in June versus USD 80.3m in May. These numbers are similar to the institutional sales numbers released by Symphony last week.

                                        1 Reply Last reply
                                        0
                                        • B Offline
                                          B Offline
                                          BiotechPro
                                          wrote on sidst redigeret af
                                          #777

                                          Fra Nordea: We expect Darzalex sales to accelerate in H2 2017, fuelled by increased penetration in second-line MM, the label expansion with Pomalyst in the US, and additional launches in Europe with a much broader second-line label. The traction in the second-line setting is likely to be the main driver for a further acceleration in sales.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger